Monopar Therapeutics Inc.MNPRNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+27.9%
5Y CAGR+31.3%
Year-over-Year Change
Research and development spending
3Y CAGR
+27.9%/yr
vs +43.8%/yr prior
5Y CAGR
+31.3%/yr
Recent deceleration
Acceleration
-15.9pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
3.9x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $15.89M | +22.2% |
| 2024 | $13.01M | +132.2% |
| 2023 | $5.60M | -26.2% |
| 2022 | $7.59M | +16.9% |
| 2021 | $6.49M | +59.7% |
| 2020 | $4.07M | +106.5% |
| 2019 | $1.97M | +11.0% |
| 2018 | $1.77M | +89.7% |
| 2017 | $935319.00 | +233.6% |
| 2016 | $280355.00 | - |